PURPOSE: Dopamine D receptors (DRs) have two affinity states for endogenous dopamine, referred to as high-affinity state (D ), which has a high affinity for endogenous dopamine, and low-affinity state (D ). The density of D can be measured with (R)-2-CHO-N-n-propylnorapomorphine ([C]MNPA), while total density of D and D (DRs) can be measured with [C]raclopride using positron emission tomography (PET). Thus, the ratio of the binding potential (BP) of [C]MNPA to that of [C]raclopride ([C]MNPA/[C]raclopride) may reflect the proportion of the density of D to that of DRs. In the caudate and putamen, [C]MNPA/[C]raclopride reflects the proportion of the density of D to that of DRs. To evaluate the reliability of the PET paradigm with [C]MNPA and [C]raclopride, we investigated the test-retest reproducibility of non-displaceable BP (BP ) measured with [C]MNPA and of [C]MNPA/[C]raclopride in healthy humans. METHODS: Eleven healthy male volunteers underwent two sets of PET studies on separate days that each included [C]MNPA and [C]raclopride scans. BP values in the caudate and putamen were calculated. Test-retest reproducibility of BP of [C]MNPA and [C]MNPA/[C]raclopride was assessed by intra-subject variability (absolute variability) and test-retest reliability (intraclass correlation coefficient: ICC). RESULTS: The absolute variability of [C]MNPA BP was 5.30 ± 3.96 % and 12.3 ± 7.95 % and the ICC values of [C]MNPA BP were 0.72 and 0.82 in the caudate and putamen, respectively. The absolute variability of [C]MNPA/[C]raclopride was 6.11 ± 3.68 % and 11.60 ± 5.70 % and the ICC values of [C]MNPA/[C]raclopride were 0.79 and 0.80 in the caudate and putamen, respectively. CONCLUSION: In the present preliminary study, the test-retest reproducibility of BP of [C]MNPA and of [C]MNPA/[C]raclopride was reliable in the caudate and putamen.
PURPOSE:Dopamine D receptors (DRs) have two affinity states for endogenous dopamine, referred to as high-affinity state (D ), which has a high affinity for endogenous dopamine, and low-affinity state (D ). The density of D can be measured with (R)-2-CHO-N-n-propylnorapomorphine ([C]MNPA), while total density of D and D (DRs) can be measured with [C]raclopride using positron emission tomography (PET). Thus, the ratio of the binding potential (BP) of [C]MNPA to that of [C]raclopride ([C]MNPA/[C]raclopride) may reflect the proportion of the density of D to that of DRs. In the caudate and putamen, [C]MNPA/[C]raclopride reflects the proportion of the density of D to that of DRs. To evaluate the reliability of the PET paradigm with [C]MNPA and [C]raclopride, we investigated the test-retest reproducibility of non-displaceable BP (BP ) measured with [C]MNPA and of [C]MNPA/[C]raclopride in healthy humans. METHODS: Eleven healthy male volunteers underwent two sets of PET studies on separate days that each included [C]MNPA and [C]raclopride scans. BP values in the caudate and putamen were calculated. Test-retest reproducibility of BP of [C]MNPA and [C]MNPA/[C]raclopride was assessed by intra-subject variability (absolute variability) and test-retest reliability (intraclass correlation coefficient: ICC). RESULTS: The absolute variability of [C]MNPA BP was 5.30 ± 3.96 % and 12.3 ± 7.95 % and the ICC values of [C]MNPA BP were 0.72 and 0.82 in the caudate and putamen, respectively. The absolute variability of [C]MNPA/[C]raclopride was 6.11 ± 3.68 % and 11.60 ± 5.70 % and the ICC values of [C]MNPA/[C]raclopride were 0.79 and 0.80 in the caudate and putamen, respectively. CONCLUSION: In the present preliminary study, the test-retest reproducibility of BP of [C]MNPA and of [C]MNPA/[C]raclopride was reliable in the caudate and putamen.
Authors: Nicholas Seneca; Sjoerd J Finnema; Lars Farde; Balázs Gulyás; Håkan V Wikström; Christer Halldin; Robert B Innis Journal: Synapse Date: 2006-04 Impact factor: 2.562
Authors: Graham Searle; John D Beaver; Robert A Comley; Massimo Bani; Andri Tziortzi; Mark Slifstein; Manolo Mugnaini; Cristiana Griffante; Alan A Wilson; Emilio Merlo-Pich; Sylvain Houle; Roger Gunn; Eugenii A Rabiner; Marc Laruelle Journal: Biol Psychiatry Date: 2010-08-15 Impact factor: 13.382
Authors: J Hirvonen; S Aalto; V Lumme; K Någren; J Kajander; H Vilkman; N Hagelberg; V Oikonen; J Hietala Journal: Nucl Med Commun Date: 2003-12 Impact factor: 1.690
Authors: Aybala Saricicek; Jason Chen; Beata Planeta; Barbara Ruf; Kalyani Subramanyam; Kathleen Maloney; David Matuskey; David Labaree; Lorenz Deserno; Alexander Neumeister; John H Krystal; Jean-Dominique Gallezot; Yiyun Huang; Richard E Carson; Zubin Bhagwagar Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-27 Impact factor: 9.236
Authors: Y Kimura; J Maeda; M Yamada; K Takahata; K Yokokawa; Y Ikoma; C Seki; H Ito; M Higuchi; T Suhara Journal: Psychopharmacology (Berl) Date: 2016-10-20 Impact factor: 4.530
Authors: Mika Naganawa; Ming-Qiang Zheng; Shannan Henry; Nabeel Nabulsi; Shu-Fei Lin; Jim Ropchan; David Labaree; Soheila Najafzadeh; Michael Kapinos; Johannes Tauscher; Alexander Neumeister; Richard E Carson; Yiyun Huang Journal: J Nucl Med Date: 2015-01-15 Impact factor: 10.057
Authors: Jean-Dominique Gallezot; Ming-Qiang Zheng; Keunpoong Lim; Shu-fei Lin; David Labaree; David Matuskey; Yiyun Huang; Yu-Shin Ding; Richard E Carson; Robert T Malison Journal: J Nucl Med Date: 2014-04-14 Impact factor: 10.057
Authors: Isadora Lopes Alves; Antoon Tm Willemsen; Rudi A Dierckx; Ana Maria M da Silva; Michel Koole Journal: J Cereb Blood Flow Metab Date: 2016-07-21 Impact factor: 6.200
Authors: N D Volkow; G-J Wang; J Logan; D Alexoff; J S Fowler; P K Thanos; C Wong; V Casado; S Ferre; D Tomasi Journal: Transl Psychiatry Date: 2015-04-14 Impact factor: 6.222